SS Innovations International (NASDAQ: SSII) has announced record second-quarter revenue of $13.9 million, a 39.4% increase year over year, driven by continued demand for its SSi Mantra surgical robotic system. The company's first-half revenue reached $25.0 million, up 65.6% from the same period in 2025, reflecting accelerated commercial traction.
The revenue growth is underpinned by a significant expansion in system installations. During the quarter, SSi Mantra installations rose 30.4% to 30 systems, bringing the total installed base to 224 systems across 12 countries. Cumulative surgeries performed on the platform reached 12,272, demonstrating growing clinical adoption and operational reliability.
The financial results highlight a robust gross profit increase of 20.0% to $7.1 million in Q2, although gross margin contracted to 50.9% from 59.1% in the prior-year quarter. For the first half, gross profit surged 77.5% to $12.4 million, with margin improvement to 49.6% from 47.7% (https://nnw.fm/zxrT1).
Investors are closely watching regulatory milestones that could serve as pivotal catalysts. The company is targeting FDA clearance for SSi Mantra by the first quarter of 2027 and EU CE marking by the end of 2026. These approvals would open access to two of the world's largest healthcare markets, potentially accelerating adoption and revenue growth.
Beyond system sales, SS Innovations is extending the clinical profile of SSi Mantra through telesurgery achievements. These advancements position the platform as a versatile tool capable of remote surgical procedures, which could expand its addressable market and differentiate it from competitors.
However, system installations remain the primary commercial growth driver. The company's strategy focuses on expanding its international footprint, with installations in 12 countries, and building a robust pipeline of procedures. The increase in cumulative surgeries underscores growing trust among surgeons and hospitals in the platform's efficacy and safety.
The company's financial performance comes amid a broader trend of rising demand for minimally invasive surgical options. Robotic-assisted surgery offers benefits such as reduced patient recovery times and lower complication rates, driving adoption across specialties.
SS Innovations' growth trajectory is not without challenges. Gross margin pressure, competitive dynamics, and regulatory hurdles could impact future performance. However, the company's strong revenue growth and expanding installed base suggest it is gaining traction in a market projected to grow significantly in the coming years.
The recent financial results and strategic milestones are detailed in the company's newsroom at https://ibn.fm/SSII, where investors can access additional information and updates.
